Trillium Therapeutics EBIT

The latest EBIT for TRIL is $65M as of September 2021. That compares with $-210M in the prior-year period — up 130.5% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Trillium Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TRIL's EBIT moved from $-210M to $65M — a 130.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Trillium Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, TRIL currently prints $65M for EBIT, while the sector average sits near $22B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Trillium Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $65M for TRIL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting TRIL's EBIT ($65M), review year-over-year change from $-210M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.